GSK raised its 2025 sales and earnings forecasts due to strong growth in specialty HIV and cancer drugs. Despite a decline in U.S. vaccine sales, the company's shares rose. New CEO Luke Miels faces challenges in driving revenue targets.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing